[{"Assets_0_Q3_USD":520510000.0,"CommonStockSharesOutstanding_0_Q3_shares":39280702.0,"EarningsPerShareBasic_1_Q3_USD":-0.46,"EarningsPerShareBasic_3_Q3_USD":-1.1,"EarningsPerShareDiluted_1_Q3_USD":-0.46,"EarningsPerShareDiluted_3_Q3_USD":-1.1,"NetIncomeLoss_1_Q3_USD":-17794000.0,"NetIncomeLoss_3_Q3_USD":-42113000.0,"StockholdersEquity_0_Q3_USD":304520000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":38654086.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":38301893.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":38654086.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":38301893.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20171107"}]